aTyr Pharma, Inc.
ATYR
$5.35
$0.408.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 10.10% | -11.60% | -4.13% | 43.49% | 42.00% |
| Gross Profit | -10.10% | 10.02% | 4.13% | -48.58% | -42.00% |
| SG&A Expenses | 47.49% | 12.89% | 12.11% | 25.93% | -10.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.31% | -6.51% | -0.87% | 39.91% | 27.71% |
| Operating Income | -17.31% | 5.19% | 0.87% | -43.82% | -27.71% |
| Income Before Tax | -19.78% | 3.91% | -1.40% | -52.19% | -32.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.78% | 3.91% | -1.40% | -52.19% | -32.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 125.00% | 0.00% | 0.00% | -- |
| Net Income | -19.78% | 3.94% | -1.40% | -52.20% | -32.16% |
| EBIT | -17.31% | 5.19% | 0.87% | -43.82% | -27.71% |
| EBITDA | -17.56% | 5.18% | 0.88% | -44.42% | -27.92% |
| EPS Basic | 3.95% | 26.58% | 27.38% | -16.23% | -0.85% |
| Normalized Basic EPS | 3.97% | 26.62% | 27.36% | -16.26% | -0.86% |
| EPS Diluted | 3.95% | 26.58% | 27.38% | -16.23% | -0.85% |
| Normalized Diluted EPS | 3.97% | 26.62% | 27.36% | -16.26% | -0.86% |
| Average Basic Shares Outstanding | 24.67% | 30.88% | 39.59% | 30.95% | 31.08% |
| Average Diluted Shares Outstanding | 24.67% | 30.88% | 39.59% | 30.95% | 31.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |